Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy
Journal of Neuromuscular Diseases · 2023
DOI: 10.3233/jnd-221615 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Neuromuscular Diseases, 2023. Verfasst von Lars K Markvardsen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Attempting discontinuation of treatment in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) is recommended. However, there is no evidence based regimen for tapering off subcutaneous immunoglobulin (SCIG). This trial investigated stepwise tapering off SCIG to detect remission and the lowest effective dosage. During tapering off, frequent vs less frequent clinical evaluation was compared.
Methods
Patients with CIDP receiving a stable SCIG dosage followed a standardized tapering off regimen: 90%, 75%, 50%, 25% and 0% of the initial dose every 12th week, pending no deterioration occurred. In case of relapse during tapering off, the lowest effective dose was identified. Treatment with SCIG was registered for two years after participation. Disability score and grip strength were primary parameters. Participants were randomized to clinical evaluation every 6th week (frequent) or 12th week (less frequent).
Results
Fifty-five patients were included of which thirty-five relapsed. Twenty patients (36%) were able to discontinue treatment without relapse. In relapsing patients, median dosage could be reduced by 10% (range, 0–75). After two years, 18 of 20 patients were still in remission without treatment. Frequent clinical evaluation did not detect deterioration more frequently than less frequent evaluation; RR 0.5 (95% CI, 0.2–1.2) ( p = 0.17).
Conclusion
In stable CIDP patients, SCIG could be completely tapered off in 36% of the patients and only in 10% of these patients relapse occurred during the following two years. More frequent evaluation was not superior to detect deterioration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Neurology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Neurology, Odense UniversityHospital, Odense, Denmark.
- Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
Zitieren
APA
Markvardsen, L. K., Sindrup, S. H., Christiansen, I., Sheikh, A. M., Holbech, J. V., & Andersen, H. (2023). Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-221615
Vancouver
Markvardsen LK, Sindrup SH, Christiansen I, Sheikh AM, Holbech JV, Andersen H. Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy. Journal of Neuromuscular Diseases. 2023. doi:10.3233/jnd-221615
BibTeX
@article{Markvardsen2023,
author = {Markvardsen, Lars K and Sindrup, Søren H and Christiansen, Ingelise and Sheikh, Aisha M and Holbech, Jakob V and Andersen, Henning},
title = {Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy},
journal = {Journal of Neuromuscular Diseases},
year = {2023},
doi = {10.3233/jnd-221615}
}
EUVIMED